These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23458731)

  • 1. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
    Warsch W; Grundschober E; Berger A; Gille L; Cerny-Reiterer S; Tigan AS; Hoelbl-Kovacic A; Valent P; Moriggl R; Sexl V
    Oncotarget; 2012 Dec; 3(12):1669-87. PubMed ID: 23458731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding a new facet to STAT5 in CML: multitasking for leukemic cells.
    Warsch W; Grundschober E; Sexl V
    Cell Cycle; 2013 Jun; 12(12):1813-4. PubMed ID: 23708512
    [No Abstract]   [Full Text] [Related]  

  • 3. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
    Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
    Turakhia SK; Murugesan G; Cotta CV; Theil KS
    J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
    Warsch W; Kollmann K; Eckelhart E; Fajmann S; Cerny-Reiterer S; Hölbl A; Gleixner KV; Dworzak M; Mayerhofer M; Hoermann G; Herrmann H; Sillaber C; Egger G; Valent P; Moriggl R; Sexl V
    Blood; 2011 Mar; 117(12):3409-20. PubMed ID: 21220747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
    Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
    J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.
    Bourgeais J; Ishac N; Medrzycki M; Brachet-Botineau M; Desbourdes L; Gouilleux-Gruart V; Pecnard E; Rouleux-Bonnin F; Gyan E; Domenech J; Mazurier F; Moriggl R; Bunting KD; Herault O; Gouilleux F
    Oncotarget; 2017 Jun; 8(26):41876-41889. PubMed ID: 27566554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
    Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
    Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
    Ishiura M; Kitai Y; Kashiwakura JI; Muromoto R; Toda J; Ichii M; Oritani K; Matsuda T
    Biochem Biophys Res Commun; 2021 Jun; 556():185-191. PubMed ID: 33845308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.
    Warsch W; Walz C; Sexl V
    Blood; 2013 Sep; 122(13):2167-75. PubMed ID: 23926299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
    Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
    J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
    Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
    Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
    Kollmann S; Grundschober E; Maurer B; Warsch W; Grausenburger R; Edlinger L; Huuhtanen J; Lagger S; Hennighausen L; Valent P; Decker T; Strobl B; Mueller M; Mustjoki S; Hoelbl-Kovacic A; Sexl V
    Leukemia; 2019 Jul; 33(7):1583-1597. PubMed ID: 30679796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
    Li Y; Yang L; Pan Y; Yang J; Shang Y; Luo J
    Oncol Rep; 2014 May; 31(5):2438-46. PubMed ID: 24647617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
    Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
    Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
    Yuan H; Wang Z; Li L; Zhang H; Modi H; Horne D; Bhatia R; Chen W
    Blood; 2012 Feb; 119(8):1904-14. PubMed ID: 22207735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
    Antoszewska-Smith J; Pawlowska E; Blasiak J
    Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.